AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04212897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Participants in the intervention arm will be asked to practice a rhythmic auditory synchronous finger tapping intervention task at home for a total of 25 minutes split between two ten-minute sets with a five-minute break between the sets every day for 8-weeks. During training sessions participants must listen to the instrumental of a pre-selected well-known Chinese melody, Moonlight over the Lotus Pond by Phoenix Legend, whose melody duration is 259s. This song was selected for its strong beat and familiarity to the participants. Participants must follow the beats of the melody and tap their right index finger simultaneously to the beats. A visual cue will be displayed to indicate the beats, identical to the one in the assessment. The training session will be conducted once daily after patients have taken their medication. Participants' primary caretaker will be asked to monitor and record completion of sessions.
Study NCT05592769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HealthBeacon Injection Care Management System (ICMS)
Description: All participants will receive access to the HealthBeacon ICMS to remotely monitor adherence to therapy in the home setting. The system includes the following items/services:~* The HealthBeacon Smart Sharps Bin~* The HealthBeacon Companion App~* HealthBeacon Care Team Support (including smart dose reminders and intervention calls)~* Waste Management Services~Participants will also be issued the following interventions to enable collection of the secondary endpoints:~-Participant Feedback Questionnaire (issued electronically upon study completion, to gather feedback on the HealthBeacon ICMS)
Study NCT05583708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400mg IV
Study NCT05583708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 dotatate
Description: 7.4GBq (200 mCi) IV
Study NCT06434233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: All patients will receive Acetaminophen 500 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Acetaminophen around the clock for the first 72 hours and as needed thereafter.
Study NCT06434233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: All patients will receive Acetaminophen 500 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Acetaminophen around the clock for the first 72 hours and as needed thereafter.
Study NCT06434233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: All patients will receive Ibuprofen 600 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Ibuprofen around the clock for the first 72 hours and as needed thereafter.
Study NCT06434233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: All patients will receive Ibuprofen 600 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Ibuprofen around the clock for the first 72 hours and as needed thereafter.
Study NCT06434233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Patients randomized to Arm 1 will receive Oxycodone 5 mg orally every 4 hours as needed x 12 tablets at post-operative discharge~Patients randomized to Arm 2 will not receive an Oxycodone prescription at post-operative discharge.~However, participants will be informed that if they need additional pain medications, these will not be withheld. Participants in the second arm who require additional pain medications will receive the same amount of Oxycodone as in arm 1
Study NCT06354790 — intervention group
Intervention type: OTHER
Intervention: Motor evaluations
Description: Evaluation of patients motor function using motor scales (MFM32, RULM), Timed functioned tests (6MWT, Rise from floor, 4SCT, 10mWT), dynamometric strength evaluation (grip, pinch, flexion/extension)
Study NCT06354790 — intervention group
Intervention type: OTHER
Intervention: Cognitive assessment
Description: Patients cognitive evaluation (WPPSI-IV, WISC-V)
Study NCT06354790 — intervention group
Intervention type: OTHER
Intervention: Pulmonary function test
Description: Evaluation of patients' respiratory function (FVC, PCF, MIP, MEP, SNIP)
Study NCT06354790 — intervention group
Intervention type: OTHER
Intervention: Cardiac evaluation
Description: Evaluation of patients' cardiac function (ECG, Echo-cardiography)
Study NCT06354790 — intervention group
Intervention type: OTHER
Intervention: Quality of life
Description: Evaluation of patients quality of life with questionnaires and PROM
Study NCT06354790 — intervention group
Intervention type: OTHER
Intervention: Spine X Ray
Description: Evaluation of spinal deformities by X-ray
Study NCT06354790 — intervention group
Intervention type: OTHER
Intervention: Muscular MRI
Description: Evaluation of a qualitative whole-body muscle part and a quantitative lower limb muscle part by MRI
Study NCT06354790 — intervention group
Intervention type: OTHER
Intervention: Biomarkers collection and analysis
Description: Collection of blood and urinary sample for biomarkers research.
Study NCT04594941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurpiridaz (18F) Injection
Description: All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein at rest.
Study NCT06477237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB0017 Q4W
Description: HB0017 at W0,1,2,4,8+HB0017Q4W
Study NCT06477237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB0017 Q8W
Description: HB0017 at W0,1,2,4,8+HB0017Q8W
Study NCT06477237 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo at W0,1,2,4,8+HB0017Q4W
Study NCT05571176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S-ketamine
Description: S-ketamine infusion 0.29 mg/kg/h for 4 hours
Study NCT05571176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: S-ketamine infusion 0.29 mg/kg/h for 4 hours
Study NCT06465134 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention
Study NCT05489419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal Prehabilitation
Description: Physical and cardiopulmonary training, personalized nutrition and treatment of anxiety and depression.
Study NCT05135156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Investigator-designed lung transplant education resource (Research Intervention)
Description: Participants will access the investigator-designed educational resource via their login to a secure website. After two weeks, participants will gain access to the publicly available website (attention control) and will have an additional two weeks of access to both of these resources.
Study NCT05135156 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Publicly available transplant education resource (Attention Control)
Description: Participants will access the publicly available education resource via their login to a secure website. After two weeks, participants will gain access to the investigator-designed educational resource (research intervention) and will have an additional two weeks of access to both of these resources.
Study NCT05635097 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivational Interviewing counseling on the Mediterranean diet and weight checks at regular intervals
Description: Each participant will meet virtually on Zoom with the DNP project leader and receive 1:1 counseling on pairing the Repnho smart scale and tape measure with the Renpho application. The expectations of the weight management program will be explained in detail during the first session, which will last one hour (session one= week zero). The weight loss goal will be at least 1-2 pounds per week as recommended by the Centers for Disease Control and Prevention (CDC) (2022).
Study NCT04720963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: intranasal remimazolam
Study NCT04720963 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water for injection
Description: intranasal distilled water for injection
Study NCT06219018 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical grade honey formulation (MGH) (L-Mesitran®)
Description: daily application of 5 grams (with applicator)
Study NCT05083806 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multispectral Optoacoustic Tomography
Description: Non-invasive optoacoustic imaging of muscular structure
Study NCT04720963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intranasal dexmedetomidine
Study NCT02293525 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReLeaf catheter
Description: Continuous infusion rate 10ml/hr (5ml/side)
Study NCT02293525 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ReLeaf catheter
Description: Continuous infusion rate 10ml/hr (5ml/side)
Study NCT02293525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT02293525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02293525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Patient-controlled analgesia (PCA) at 1mg every 6 minutes with a 4 hour lock out after 30mg
Study NCT02293525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Patient-controlled analgesia (PCA) at 1mg every 6 minutes with a 4 hour lock out after 30mg
Study NCT02293525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 10mg every 4-6 hours
Study NCT02293525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: 10mg every 4-6 hours
Study NCT04466618 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline infused during the study
Study NCT04466618 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-9,39
Description: Exendin-9,39 infused during the study
Study NCT04466618 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Saline + Intralipid/Heparin
Description: Saline infused during acute insulin resistance
Study NCT04466618 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-9,39 + Intralipid/Heparin
Description: Exendin-9,39 infused during acute insulin resistance
Study NCT05083806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral Optoacoustic Tomography
Description: Non-invasive optoacoustic imaging of muscular structure
Study NCT05537649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oatmeal porridge
Description: Investigation of the impact of enzymatic modification of the molecular structure of starch by amylomaltase on the postprandial glycemic responses of an oatmeal porridge.
Study NCT05051124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Delivery of Medications
Description: The study team will adopt a novel approach of extending beyond the use of peer support in the clinical setting and implement door-to-door peer delivery of medications within patients' communities
Study NCT05051124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Information Technology (HIT) Platform
Description: To support peer delivery, the study team will use a HIT platform that performs 4 core functions: 1) tailored counseling strategies through decision support; 2) teleconsultation support for clinician-peer-patient interactions; 3) tracking medication refills to enhance accountability of the peer delivery process; and 4) analytics to improve medication supply chain by generating patient-level drug consumption data. This is an innovative use of HIT to accomplish these functions to support medication adherence.
Study NCT05404698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: EX: 30 min of aerobic exercise (3/10 Borg scale) during hemodialysis treatment (between 30 min and 3h of treatment).
Study NCT05404698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: CONT: participants will receive hemodialysis treatment only (usual care)
Study NCT05764590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP-306
Description: A blood phosphorus lowering drug with a novel mechanism
Study NCT05764590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer Carbonate
Description: A phosphate binder
Study NCT05156645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCTA01 and SCTA01C
Description: Diluted by 0.9% normal saline
Study NCT05472519 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood samples
Description: Only one visit for each participant: A large majority of visits will be part of patients' usual care.~* Medical examination : weight, gender, blood pressure, medical history~* Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma
Study NCT05472519 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood samples
Description: Only one visit for each participant:~* Medical examination : weight, gender, blood pressure, medical history~* Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma
Study NCT05156645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluted by 0.9% normal saline
Study NCT06336278 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pressure Algometer
Description: Pressure algometer is used to detect pain pressure treshold.
Study NCT06182384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Receive a single dose of 240mg SHR-1314 at every period (First period：1mL AI, injection two needles. Second period: 2mL AI, injection one needle).
Study NCT06182384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Receive a single dose of 240mg SHR-1314 at every period (First period：2mL AI, injection one needle. Second period: 1mL AI, injection two needles).
Study NCT05183321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal therapy
Description: periodontal cleaning
Study NCT05641714 — intervention group
Intervention type: OTHER
Intervention: L test
Description: The test includes standing up from a chair, walking in a straight line for 3 m, turning to the right, walking in a straight line for 7 m, turning around, walking back 7 m along the same line, turning to the left, walk 3 m in a straight line to the chair, and then sit down.
Study NCT05527847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peers LEAD
Description: Two group session focusing on beliefs about medicines and diabetes, discrimination/mistrust, and communication with providers, and 2 peer-based phone calls from Ambassadors to occur weekly for weeks 3-8, then bi-weekly for weeks 9-12.
Study NCT05527847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HLWD
Description: Weekly group sessions for two months. Sessions will last up to 2.5 hours and focus on a different diabetes self-management topic.
Study NCT05641714 — intervention group
Intervention type: OTHER
Intervention: Timed Up and Go test
Description: The test requires the individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.
Study NCT05641714 — intervention group
Intervention type: OTHER
Intervention: 10 meter walk test
Description: In the test, the clinician measures the time taken to walk a distance of 10 m from a standing position. Participants are asked to walk along a 14 m long walkway.
Study NCT05641714 — intervention group
Intervention type: OTHER
Intervention: Six Minute Walk Test
Description: This test measures the distance (in m) that an individual is able to walk at a comfortable speed for 6 minutes. Starting from a standing position, participants walk continuously around two pylons placed 30 m apart for 6 minutes. The distance is recorded end of the test.
Study NCT05641714 — intervention group
Intervention type: OTHER
Intervention: The timed 360° turn test
Description: Each participant turns around in place in a standing position for both sides.
Study NCT05694533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INDV-2000
Description: Capsules administered orally twice a day
Study NCT05694533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam syrup administered orally on Days 1 and 15
Study NCT05527847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HLWD
Description: Weekly group sessions for two months. Sessions will last up to 2.5 hours and focus on a different diabetes self-management topic.
Study NCT06183619 — intervention group
Intervention type: PROCEDURE
Intervention: Pulmonary vein isolation plus superior vena cava isolation
Description: Pulmonary vein isolation plus superior vena cava isolation
Study NCT06183619 — intervention group
Intervention type: PROCEDURE
Intervention: Pulmonary vein isolation
Description: Pulmonary vein isolation only
Study NCT04687748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromographic Biofeedback
Description: Surface EMG biofeedback is an adjunct therapy to standard exercise regime for increasing muscle strength. Electromyographic biofeedback is a specific form of biofeedback. The device records muscle activity through application of vaginal probe will be inserted in vagina and the reference surface electrode would be placed over the right anterior superior iliac spine.
Study NCT04687748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFM exercises
Description: Patients would be advised to maximally contract the pelvic floor muscles as forcefully a possible for about 5 seconds. Three attempts would be made with 40 seconds rest in between each contraction. The exercises would be performed with the patient initially in supine position, with hip and knee flexed at 30 and 90 degrees.
Study NCT06347770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Blend Oral Tablet
Description: In our study, forty pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 #106 CFU) by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered four tablets three times a day (2 g/d) for seven days before surgery until the fourth day after surgery.
Study NCT05428592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LVRNA009
Description: 50μg /0.5 mL/Vial/person
Study NCT05428592 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac®
Description: 0.5 mL/Vial, 0.5mL per human dose containing 600SU of inactivated SARS-CoV-2 antigen
Study NCT06294483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CBC
Description: Is used to detect haematological indices (mean platelet volume, platelet lymphocyte ratio and neutrophil lymphocyte ratio) and its relation to disease activity
Study NCT06294483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Antinuclear Antibody tests (ANA)
Description: To be tool in diagnosis of SLE
Study NCT06294483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rest of ANA profile
Description: As tool of diagnosis of SLE
Study NCT06294483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: C3 and C4 complement level.
Description: As method of detection of acute acivity of SLE
Study NCT06294483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anti phospholipid marker
Description: To detect antiphospholipid syndrome if there is sign of thrombosis
Study NCT06294483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum creatinine and Alb/create ratio
Description: To detct complication of disease on kidney
Study NCT06361615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single-Task
Description: Single-task (ST) training group developed an exercise program based on Functional Exercise Circuit (FEC) protocol. This exercise program has been published previously12, which considered 15 different exercises in a functional exercise circuit.
Study NCT06361615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-Task
Description: DT training (multicomponent physical exercise + cognitive tasks)
Study NCT03696485 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCM-010
Description: SCM-010 is comprised of adipose derived expanded mesenchymal cells (ADSC), suspended in Plasma-Lyte and intended for intrathecal (IT) administration.
Study NCT05209711 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Femoral nerve block under ultrasound control with a electrostimulator peripheral nerves 7.5 ml 1% lidocaine
Description: Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated (7.5 ml 1% lidocaine).If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed.